| 1 |
Le Berre C， Honap S， Peyrin-Biroulet L. Ulcerative colitis ［J］. Lancet，2023， 402（10401）： 571-584.
|
| 2 |
Zhang Y， Chu X， Wang L， et al. Global patterns in the epidemiology，cancer risk， and surgical implications of inflammatory bowel disease［J］. Gastroenterol Rep （Oxf）， 2024， 12： goae053.
|
| 3 |
Balram B， Joshi H， Wong K， et al. Concomitant 5-aminosalicylate therapy in moderate-to-severe ulcerative colitis patients escalated to infliximab is not beneficial ［J］. Dig Dis Sci， 2021， 66（11）： 3985-3992.
|
| 4 |
Singh S， Proudfoot JA， Dulai PS， et al. No benefit of concomitant 5-aminosalicylates in patients with ulcerative colitis escalated to biologic therapy： pooled analysis of individual participant data from clinical trials ［J］. Am J Gastroenterol， 2018， 113（8）： 1197-1205.
|
| 5 |
Ungaro RC， Kadali H， Zhang W， et al. Impact of concomitant 5-aminosalicylic acid therapy on vedolizumab efficacy and safety in inflammatory bowel disease： post hoc analyses of clinical trial data ［J］.J Crohns Colitis， 2023， 17（12）： 1949-1961.
|
| 6 |
卢佳豪， 方露燕， 曹曙光， 等. 维得利珠单抗治疗溃疡性结肠炎的疗效及其影响因素 ［J］. 中华医学杂志， 2024， 104（39）： 3669-3675.
|
| 7 |
Nishida Y， Hosomi S， Fujimoto K， et al. Evaluating the effects of 5-aminosalicylic acid on tofacitinib treatment in ulcerative colitis ［J］. J Gastroenterol Hepatol， 2025， 40（1）： 108-114.
|
| 8 |
Panaccione R， Ghosh S， Middleton S， et al. Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis ［J］. Gastroenterology， 2014， 146（2）： 392-400.e3.
|
| 9 |
Targownik LE， Benchimol EI， Bernstein CN， et al. Combined biologic and immunomodulatory therapy is superior to monotherapy for decreasing the risk of inflammatory bowel disease-related complications ［J］. J Crohns Colitis， 2020， 14（10）： 1354-1363.
|
| 10 |
Ito A， Omori T， Nakamura S， et al. Retrospective investigation of tacrolimus combined with an anti-tumor necrosis factorα antibody as remission induction therapy for refractory ulcerative colitis： efficacy，safety， and relapse rate ［J］. JGH Open. 2019， 3（6）： 525-531.
|
| 11 |
Christensen B， Gibson PR， Micic D， et al. Safety and efficacy of combination treatment with calcineurin inhibitors and vedolizumab in patients with refractory inflammatory bowel disease ［J］. Clin Gastroenterol Hepatol， 2019， 17（3）： 486-493.
|
| 12 |
Manzini R， Schwarzfischer M， Atrott K， et al. Combination of vedolizumab with tacrolimus is more efficient than vedolizumab alone in the treatment of experimental colitis ［J］. Inflamm Bowel Dis， 2021，27（12）： 1986-1998.
|
| 13 |
Yzet C， Diouf M， Singh S， et al. No benefit of concomitant immunomodulator therapy on eficacy of biologics that are not tumor necrosis factor antagonists in patients with inflammatory bowel diseases： a meta-analysis ［J］. Clin Gastroenterol Hepatol， 2021， 19（4）：668-679.e8.
|
| 14 |
Hu A， Kotze PG， Burgevin A， et al. Combination therapy does not improve rate of clinical or endoscopic remission in patients with inflammatory bowel diseases treated with vedolizumab or ustekinumab［J］. Clin Gastroenterol Hepatol， 2021， 19（7）： 1366-1376.e2.
|
| 15 |
Watanabe K， Peyrin-Biroulet L， Danese S， et al. Impact of concomitant thiopurine on the efficacy and safety of filgotinib in patients with ulcerative colitis： post hoc analysis of the phase 2b/3 selection study ［J］.J Crohns Colitis， 2024， 18（6）： 801-811.
|
| 16 |
Liang Y， Li Y， Lee C， et al. Ulcerative colitis： molecular insights and intervention therapy ［J］. Mol Biomed， 2024， 5（1）： 42.
|
| 17 |
Gubatan J， Keyashian K， Rubin SJS， et al. Anti-integrins for the treatment of inflammatory bowel disease： current evidence and perspectives ［J］. Clin Exp Gastroenterol， 2021， 14： 333-342.
|
| 18 |
Soler D， Chapman T， Yang LL， et al. The binding specificity and selective antagonism of vedolizumab， an anti-alpha4beta7 integrin therapeutic antibody in development for inflammatory bowel diseases［J］. J Pharmacol Exp Ther， 2009， 330（3）： 864-875.
|
| 19 |
Buer LCT， Høivik ML， Warren DJ， et al. Combining anti-TNF-α and vedolizumab in the treatment of inflammatory bowel disease： a case series ［J］. Inflamm Bowel Dis， 2018， 24（5）： 997-1004.
|
| 20 |
Wlazlo M， Meglicka M， Wiernicka A， et al. Combination biologic therapy in pediatric inflammatory bowel disease： safety and efficacy over a minimum 12-month follow-up period ［J］. J Pediatr Gastroenterol Nutr， 2024， 79（1）： 54-61.
|
| 21 |
Ahmed W， Galati J， Kumar A， et al. Dual biologic or small molecule therapy for treatment of inflammatory bowel disease： a systematic review and meta-analysis ［J］. Clin Gastroenterol Hepatol， 2022， 20（3）：e361-e79.
|
| 22 |
Verstockt B， Salas A， Sands BE， et al. IL-12 and IL-23 pathway inhibition in inflammatory bowel disease ［J］. Nat Rev Gastroenterol Hepatol， 2023， 20（7）： 433-446.
|
| 23 |
Benson JM， Peritt D， Scallon BJ， et al. Discovery and mechanism of ustekinumab： a human monoclonal antibody targeting interleukin-12 and interleukin-23 for treatment of immune-mediated disorders ［J］.MAbs， 2011， 3（6）： 535-45.
|
| 24 |
Peyrin-Biroulet L， Allegretti JR， Rubin DT， et al. Guselkumab in patients with moderately to severely active ulcerative colitis： Quasar phase 2b induction study ［J］. Gastroenterology， 2023， 165（6）： 1443-1457.
|
| 25 |
Feagan BG， Sands BE， Sandborn WJ， et al. VEGA study group.Guselkumab plus golimumab combination therapy versus guselkumab or golimumab monotherapy in patients with ulcerative colitis （VEGA）：a randomised， double-blind， controlled， phase 2， proof-of-concept trial［J］. Lancet Gastroenterol Hepatol， 2023， 8（4）： 307-320.
|
| 26 |
Biscaglia G， Piazzolla M， Cocomazzi F， et al. Landmarks for dual biological therapy in inflammatory bowel disease： lesson from two case reports of vedolizumab in combination with ustekinumab ［J］. Eur J Gastroenterol Hepatol， 2020， 32（12）： 1579-1582.
|
| 27 |
Filipiuk A， Gonciarz M. Rare extraintestinal manifestations of ulcerative colitis treated with dual biologic therapy： a case report ［J］.World J Clin Cases， 2024， 12（23）： 5441-5447.
|
| 28 |
Chen Z， Jiang P， Su D， et al. Therapeutic inhibition of the JAK-STAT pathway in the treatment of inflammatory bowel disease ［J］. Cytokine Growth Factor Rev， 2024， 79： 1-15.
|
| 29 |
Salas A， Hernandez-Rocha C， Duijvestein M， et al. JAK-STAT pathway targeting for the treatment of inflammatory bowel disease ［J］.Nat Rev Gastroenterol Hepatol， 2020， 17（6）： 323-337.
|
| 30 |
Spalinger MR， Sayoc-Becerra A， Ordookhanian C， et al. The JAK inhibitor tofacitinib rescues intestinal barrier defects caused by disrupted epithelial-macrophage interactions ［J］. J Crohns Colitis，2021， 15（3）： 471-484.
|
| 31 |
Traves PG， Murray B， Campigotto F， et al. JAK selectivity and the implications for clinical inhibition of pharmacodynamic cytokine signalling by filgotinib， upadacitinib， tofacitinib and baricitinib ［J］.Ann Rheum Dis， 2021， 80（7）： 865-875.
|
| 32 |
Scheinberg AR， Dauer RM， Damas OM， et al. S0895 Is two better than one？ Combination therapy with vedolizumab and tofacitinib for the treatment of patients with inflammatory bowel disease ［J］. Am J Gastroenterol， 2020， 115 （1）： S460-S461.
|
| 33 |
Llano EM， Shrestha S， Burstein E， et al. Favorable outcomes combining vedolizumab with other biologics or tofacitinib for treatment of inflammatory bowel disease ［J］. Crohns Colitis 360， 2021，3（3）： otab030.
|
| 34 |
Taberner Bonastre P， Torres Vicente G， Cano-Marron M， et al.A patient with ulcerative colitis treated with a combination of vedolizumab and tofacitinib ［J］. Eur J Hosp Pharm， 2021， 28（6）： 353-355.
|
| 35 |
Glassner K， Oglat A， Duran A， et al. The use of combination biological or small molecule therapy in inflammatory bowel disease： a retrospective cohort study ［J］. J Dig Dis， 2020， 21（5）： 264271.
|
| 36 |
Alayo QA， Khatiwada A， Patel A， et al. Effectiveness and safety of combining tofacitinib with a biologic in patients with refractory inflammatory bowel diseases ［J］. Inflamm Bowel Dis， 2021， 27（10）：1698-1702.
|
| 37 |
Lee JA， Magavi PR， Konijeti GG. Treatment of ulcerative colitis and seronegative inflammatory spondyloarthritis with vedolizumab and tofacitinib ［J］. Inflamm Bowel Dis， 2020， 26（11）： e146.
|
| 38 |
Le Berre C， Loeuille D， Peyrin-Biroulet L. Combination therapy with vedolizumab and tofacitinib in a patient with ulcerative colitis and spondyloarthropathy ［J］. Clin Gastroenterol Hepatol， 2019， 17（4）： 794-796.
|
| 39 |
Kuehbacher T， Leick A， vonGogh G， et al. Mo1906 - combination therapy of vedolizumab and tofacitinib in IBD patients with chronic active refractory disease course and spondylarthritis ［J］.Gastroenterology， 2019， 156（6）： S-881.
|